

23 - References

References

676 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 References

1. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. NICE Guidance [NG97]. 2018 (last checked September 2023, last accessed December 2023); <https://www.nice.org.uk/guidance/ng97>.
2. Steinberg M, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. *Int J Geriatr Psychiatry* 2008; 23:170-177.
3. Salzman C, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. *J Clin Psychiatry* 2008; 69:889-898.
4. Department of Health. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services by Professor Sube Banerjee. 2009; <https://psychrights.org/research/digest/nlps/banerjeereportongeriatricneurolepticuse.pdf>.
5. Livingston G, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. *Health Technol Assess* 2014; 18:1-226, v-vi.
6. Kales HC, et al. Assessment and management of behavioral and psychological symptoms of dementia. *BMJ* 2015; 350:h369.
7. James IA. *Understanding Behaviour in Dementia That Challenges: A Guide to Assessment and Treatment*. London: Jessica Kingsley Publishers; 2011.
8. Brechin D, et al. British Psychological Society. Briefing paper. Alternatives to antipsychotic medication: psychological approaches in managing psychological and behavioural distress in people with dementia. 2013; <https://explore.bps.org.uk/content/report--guideline/bpsrep.2013.inf207>.
9. Douglas S, et al. Non-pharmacological interventions in dementia. *Adv Psychiatric Treat* 2004; 10:171-177.
10. Ayalon L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. *Arch Intern Med* 2006; 166:2182-2188.
11. Livingston G, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. *Am J Psychiatry* 2005; 162:1996-2021.
12. Abraha I, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. *The*

- SENATOR-OnTop series. *BMJ Open* 2017; 7:e012759.
13. Dyer SM, et al. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. *Int Psychogeriatr* 2018; 30:295–309.
 14. Chen H, et al. Effects of animal-assisted therapy on patients with dementia: a systematic review and meta-analysis of randomized controlled trials. *Psychiatry Res* 2022; 314:114619.
 15. Santagata F, et al. The doll therapy as a first line treatment for behavioral and psychological symptoms of dementia in nursing homes residents: a randomized, controlled study. *BMC Geriatr* 2021; 21:545.
 16. Guu TW, et al. Light, sleep-wake rhythm, and behavioural and psychological symptoms of dementia in care home patients: revisiting the sundowning syndrome. *Int J Geriatr Psychiatry* 2022; 37:10.
 17. Kolberg E, et al. The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial. *BMC Psychiatry* 2021; 21:377.
 18. Steichele K, et al. The effects of exercise programs on cognition, activities of daily living, and neuropsychiatric symptoms in community-dwelling people with dementia – a systematic review. *Alzheimers Res Ther* 2022; 14:97.
 19. Ball EL, et al. Aromatherapy for dementia. *Cochrane Database Syst Rev* 2020; 8:CD003150.
 20. Husebo BS, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. *BMJ* 2011; 343:d4065.
 21. Manietta C, et al. Algorithm-based pain management for people with dementia in nursing homes. *Cochrane Database Syst Rev* 2022; 4:CD013339.
 22. Brown R, et al. Opioids for agitation in dementia. *Cochrane Database Syst Rev* 2015; 5:CD009705.
 23. Lee PE, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. *BMJ* 2004; 329:75.
 24. Jeste DV, et al. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. *Harv Rev Psychiatry* 2005; 13:340–351.
 25. Jeste DV, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. *Neuropsychopharmacology* 2008; 33:957–970.
 26. Aupperle P. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. *Am J Alzheimers Dis Other Demen* 2006; 21:101–108.
 27. Yury CA, et al. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. *Psychother Psychosom* 2007; 76:213–218.
 28. Deberdt WG, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. *Am J Geriatr Psychiatry* 2005; 13:722–730.
 29. Schneider LS, et al. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am J Geriatr Psychiatry* 2006; 14:191–210.
 30. Anon. How safe are antipsychotics in dementia? *Drug Ther Bull* 2007; 45:81–86.
 31. Rosack J. Side-effect risk often tempers antipsychotic use for dementia. *Psychiatr News* 2006; 41:1–38.

32. Schneider LS, et al. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005; 294:1934–1943.

Prescribing in older people CHAPTER 6

33. Bessey LJ, et al. Management of behavioral and psychological symptoms of dementia. *Curr Psychiatry Rep* 2019; 21:66.

34. Ballard C, et al. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease (review). *Cochrane Database Syst Rev* 2006; 1:CD003476.

35. Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. *CNS Spectr* 2016; 21:1–6.

36. Lee D, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. *JAMA Neurol* 2023; 80:1307–1316.

37. US Food and Drug Administration. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease. 2023 (last accessed January 2024); <https://www.fda.gov/news-events/press-announcements/fda--approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease>.

38. Gov.UK. PhVWP assessment report: antipsychotics and cerebrovascular accident. 2005; <https://www.gov.uk/government/publications/antipsychotic-medicines-licensed-products-uses-and-side-effects>.

39. Duff G. Atypical antipsychotic drugs and stroke – Committee on Safety of Medicines. 2004; <https://webarchive.nationalarchives.gov.uk/20141206131857/http://www.mhra.gov.uk/home/groups/pl--p/documents/websitesresources/con019488.pdf>.

40. US Food and Drug Administration. Information on conventional antipsychotics – FDA alert [6/16/2008]. 2008; <http://www.fda.gov/>.

41. European Medicines Agency. CHMP assessment report on conventional antipsychotics. 2008; <http://www.emea.europa.eu>.

42. Huybrechts KF, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. *BMJ* 2012; 344:e977.

43. Kales HC, et al. Risk of mortality among individual antipsychotics in patients with dementia. *Am J Psychiatry* 2012; 169:71–79.

44. Schmedt N, et al. Comparative risk of death in older adults treated with antipsychotics: a population-based cohort study. *Eur Neuropsychopharmacol* 2016; 26:1390–1400.

45. Maust DT, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. *JAMA Psychiatry* 2015; 72:438–445.

46. Yunusa I, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. *JAMA Network Open* 2019; 2:e190828.

47. Tampi RR, et al. Prazosin for the management of behavioural and psychological symptoms of dementia. *Drugs Context* 2022; 11;2022-3-3.

48. Corbett A, et al. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. *BMJ* 2014; 349:g6420.

49. Janssen-Cilag Ltd. Summary of product characteristics. RISPERDAL CONSTA 25mg, 37.5mg, 50mg powder and solvent for prolonged- release suspension for injection. 2022 (last accessed December 2023); <https://www.medicines.org.uk/emc/product/1690/smpc#gref>.

50. Joint Formulary Committee. British National Formulary (online). London: BMJ and Pharmaceutical Press; <http://www.medicinescomplete.com>.

51. Katz IR, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. *J Clin Psychiatry* 1999; 60:107–115.

52. Kyle K, et al. Treatment of psychosis in Parkinson's disease and dementia with Lewy bodies: a review. *Parkinsonism Relat Disord* 2020; 75:55–62.

53. Brodaty H, et al. Antipsychotic deprescription for older adults in long-term care: the HALT Study. *J Am Med Dir Assoc* 2018; 19:592–600.e597.

54. Ballard C, et al. The Dementia Antipsychotic Withdrawal Trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. *Lancet Neurol* 2009; 8:151–157.

55. Gedde MH, et al. Less is more: the impact of

deprescribing psychotropic drugs on behavioral and psychological symptoms and daily functioning in nursing home patients. results from the cluster-randomized controlled COSMOS Trial. *Am J Geriatr Psychiatry* 2021; 29:304–315. 56. Cossette B, et al. Optimizing practices, use, care, and services-antipsychotics (OPUS-AP) in long-term care centers in Quebec, Canada: a successful scale-up. *J Am Med Dir Assoc* 2022; 23:1084–1089. 57. NHS PrescQIPP. T7: reducing antipsychotic prescribing in dementia. 2014; <https://www.prescqipp.info/our-resources/bulletins/t7-reducing-antipsychotic-prescribing-in-dementia/>. 58. Bjerre LM, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. *Can Fam Physician* 2018; 64:17–27. 59. Campbell N, et al. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: a meta-analysis. *Clin Interv Aging* 2008; 3:719–728. 60. Seibert M, et al. Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials. *Alzheimers Res Ther* 2021; 13:131. 61. Verdoux H, et al. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. *Psychol Med* 2005; 35:307–315. 62. Lagnaoui R, et al. Benzodiazepine utilization patterns in Alzheimer’s disease patients. *Pharmacoepidemiol Drug Saf* 2003; 12:511–515. 63. Billioti de Gage S, et al. Benzodiazepine use and risk of dementia: prospective population based study. *BMJ* 2012; 345:e6231. 64. Taipale H, et al. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. *CMAJ* 2017; 189:e519–e529. 65. Palmaro A, et al. Benzodiazepines and risk of death: results from two large cohort studies in France and UK. *Eur Neuropsychopharmacol* 2015; 25:1566–1577. 66. Chang CM, et al. Benzodiazepine and risk of hip fractures in older people: a nested case-control study in Taiwan. *Am J Geriatr Psychiatry* 2008; 16:686–692.

678 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 67. Aboukhatwa M, et al. Antidepressants are a rational complementary therapy for the treatment of Alzheimer’s disease. *Mol Neurodegener* 2010; 5:10. 68. Burley CV, et al. Nonpharmacological approaches reduce symptoms of depression in dementia: a systematic review and meta-analysis. *Ageing Res Rev* 2022; 79:101669. 69. Porsteinsson AP, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. *JAMA* 2014; 311:682–691. 70. Martinon-Torres G, et al. Trazodone for agitation in dementia. *Cochrane Database Syst Rev* 2004; 4:CD004990. 71. McCleery J, et al. Pharmacotherapies for sleep disturbances in dementia. *Cochrane Database Syst Rev* 2016; 11:CD009178. 72. Trieu C, et al. Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review. *Cogn Behav Neurol* 2020; 33:1–15. 73. Scoralick FM, et al. Mirtazapine does not improve sleep disorders in Alzheimer’s disease: results from a double-blind, placebo-controlled pilot study. *Psychogeriatrics* 2017; 17:89–96. 74. Banerjee S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. *Lancet* 2021; 398:1487–1497. 75. Cumbo E, et al. Treatment effects of vortioxetine on cognitive functions in mild Alzheimer’s disease patients with depressive symptoms: a 12 month, open-label, observational study. *J Prev Alzheimers Dis* 2019; 6:192–197. 76. Jeong HW, et al. Vortioxetine treatment for depression in Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. *Clin Psychopharmacol Neurosci* 2022; 20:311–319. 77. Santos García D, et al. Vortioxetine improves depressive symptoms and cognition in Parkinson’s disease patients with major depression: an open-label prospective study. *Brain Sci* 2022; 12:1466. 78. Ballard C, et al. Management of neuropsychiatric symptoms in people

with dementia. *CNS Drugs* 2010; 24:729–739. 79. Wang YC, et al. Increased risk of dementia in patients with antidepressants: a meta-analysis of observational studies. *Behav Neurol* 2018; 2018:5315098. 80. Sommer OH, et al. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. *Dement Geriatr Cogn Disord* 2009; 27:155–163. 81. Tariot PN, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. *Am J Psychiatry* 1998; 155:54–61. 82. Lonergan E, et al. Valproate preparations for agitation in dementia. *Cochrane Database Syst Rev* 2009; 3:CD003945. 83. Konovalov S, et al. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. *Int Psychogeriatr* 2008; 20:293–308. 84. Yeh YC, et al. Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review. *Kaohsiung J Med Sci* 2012; 28:185–193. 85. Sival RC, et al. Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study. *Int J Geriatr Psychiatry* 2004; 19:305–312. 86. Baillon SF, et al. Valproate preparations for agitation in dementia. *Cochrane Database Syst Rev* 2018; 10:CD003945. 87. Tariot PN, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. *Arch Gen Psychiatry* 2011; 68:853–861. 88. Supasitthumrong T, et al. Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. *Br J Clin Pharmacol* 2019; 85:690–703. 89. Cooney C, et al. Use of low-dose gabapentin for aggressive behavior in vascular and mixed vascular/Alzheimer dementia. *J Neuropsychiatry Clin Neurosci* 2013; 25:120–125. 90. Gallagher D, et al. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? *Drugs* 2014; 74:1747–1755. 91. David R, et al. Non-pharmacologic management of sleep disturbance in Alzheimer’s disease. *J Nutr Health Aging* 2010; 14:203–206. 92. Javed B, et al. Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer’s disease. *Expert Rev Neurother* 2023; 23:501–514. 93. McCleery J, et al. Pharmacotherapies for sleep disturbances in dementia. *Cochrane Database Syst Rev* 2020; 11:CD009178. 94. Roland JP, et al. Impact of pharmacotherapy on insomnia in patients with Alzheimer’s disease. *Drugs Aging* 2021; 38:951–966. 95. Bishara D, et al. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. *Int J Geriatr Psychiatry* 2017; 32:650–656. 96. Porsteinsson AP, et al. An update on the advancements in the treatment of agitation in Alzheimer’s disease. *Expert Opin Pharmacother* 2017; 18:611–620. 97. Carrarini C, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. *Front Neurol* 2021; 12:644317. 98. Savaskan E, et al. Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. *Int Psychogeriatr* 2018; 30:285–293. 99. Tariot PN, et al. Trial of pimavanserin in dementia-related psychosis. *N Engl J Med* 2021; 385:309–319. 100. DeKarske D, et al. An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson’s disease and depression. *J Parkinsons Dis* 2020; 10:1751–1761. 101. ClinicalTrials.gov. ITI-007 for the treatment of agitation in patients with dementia, including Alzheimer’s disease [NCT02817906]. 2021; <https://clinicaltrials.gov/study/NCT02817906>.

Prescribing in older people CHAPTER 6 102. Tampi RR, et al. Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia. *World J Psychiatry* 2020; 10:29–33. 103. Ahmed M, et al. Current agents in development for treating behavioral and psychological symptoms associated with dementia. *Drugs Aging* 2019; 36:589–605. 104. Lanctôt KL, et al. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. *Am J Geriatr Psychiatry* 2023; 31:1077–1087. 105. Chen A, et al. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on management of behavioral and

psychological symptoms in dementia. *Psychiatry Res* 2021; 295:113641. 106. Bosnjak Kuharic D, et al. Cannabinoids for the treatment of dementia. *Cochrane Database Syst Rev* 2021; 9:CD012820.

Revision #1

Created 2026-01-04 20:17:02 UTC by Omar Ayman

Updated 2026-01-04 20:17:02 UTC by Omar Ayman